ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Small Cell Lung Carcinoma
Cancer
Colorectal Cancer
Neoplasm Metastasis
Breast Cancer
Squamous Cell Carcinoma of Head and Neck

Lung Cancer trials near Rochester, MN, USA:

Locations recently updated

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung (VISUALIZE-2)

a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer...

Enrolling
Lung Cancer
Lung Metastases
Drug: Abenacianine
Other: Near Infrared (NIR) Imaging

Phase 3

Vergent Bioscience

Rochester, Minnesota, United States and 8 other locations

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung...

Enrolling
Carcinoma Non Small Cell Lung
Advanced Non Small Cell Lung Cancer
Drug: Sarilumab
Drug: Marlotamig

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Rochester, Minnesota, United States and 17 other locations

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NS...

Enrolling
Advanced Lung Cancer
Biological: BNT327
Biological: BNT324

Phase 1, Phase 2

BioNTech
BioNTech

Rochester, Minnesota, United States and 90 other locations

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...

Enrolling
Extensive Stage-small Cell Lung Cancer
Drug: Carboplatin
Drug: Ifinatamab deruxtecan

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

Rochester, Minnesota, United States and 59 other locations

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decid ...

Enrolling
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Drug: SMS001

Phase 2

ToLymph Inc.

Rochester, Minnesota, United States and 1 other location

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sit...

Enrolling
Small Cell Lung Cancer
Drug: Topotecan
Drug: Lurbinectedin

Phase 3

AbbVie
AbbVie

Rochester, Minnesota, United States and 71 other locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the ...

Enrolling
Non-small Cell Lung Cancer
Drug: Nab-paclitaxel
Drug: Pembrolizumab

Phase 3

AstraZeneca
AstraZeneca

Rochester, Minnesota, United States and 332 other locations

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS...

Active, not recruiting
Small-Cell Lung Cancer
Extensive-Stage Small-Cell Lung Cancer
Drug: Tarlatamab
Drug: Durvalumab

Phase 3

Amgen
Amgen

Rochester, Minnesota, United States and 224 other locations

Locations recently updated

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung ...

Active, not recruiting
Non-Small-Cell Lung Cancer
Drug: Amivantamab
Drug: Carboplatin

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Rochester, Minnesota, United States and 71 other locations

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

Phase 2

AbbVie
AbbVie

Rochester, Minnesota, United States and 254 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems